Status:
COMPLETED
Clinical Deployment and Validation of Rho
Lead Sponsor:
16 Bit Inc.
Collaborating Sponsors:
Amgen
Sunnybrook Health Sciences Centre
Conditions:
Low Bone Density
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
Osteoporosis is a widespread disease characterized by the loss of bone mineral density (BMD). 16 Bit has developed software, called RhoTM, that analyzes various x-rays, performed in patient age 50 and...
Detailed Description
Osteoporosis is a widespread disease characterized by the loss of bone mineral density (BMD). 16 Bit has developed an opportunistic screening tool for low BMD, called RhoTM, that analyzes lumbar spine...
Eligibility Criteria
Inclusion
- age 50+ years
- outpatient undergoing x-ray examinations of:
- chest
- thoracic spine
- lumbar spine
- pelvis
- knee
- hand/wrist
Exclusion
- age \< 50 years
- inpatient
Key Trial Info
Start Date :
November 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
1146 Patients enrolled
Trial Details
Trial ID
NCT05245851
Start Date
November 21 2022
End Date
October 1 2023
Last Update
August 19 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
2
Holland Orthopaedic & Arthritic Centre
Toronto, Ontario, Canada, M4Y 1H1